Who Paid My Doc
Mark Ewalt
Molecular Genetic Pathology New York, NY Medical Doctor
NPI 1497998512 CMS profile 576737
1275 York Avenue, Dept Of Pathology, Box #36, New York, NY 10065
General payments
$38,399
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mark Ewalt of New York, NY is reported in the CMS Open Payments database as having received $38,399 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $27,228 | 10 | |
| 2024 | General | $2,126 | 2 | |
| 2023 | General | $105 | 1 | |
| 2021 | General | $1,900 | 1 | |
| 2020 | General | $7,040 | 1 |
Beside peers
- Mark Ewalt
- Molecular Genetic Pathology median
- Middle half of Molecular Genetic Pathology
- National median
In program year 2025, general payments to Mark Ewalt were reported at $27,228. Among 27 Molecular Genetic Pathology profiles paid that year, the median was $225 and the middle half received between $91 and $3,596.
Show as a table
| Year | Mark Ewalt | Molecular Genetic Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $131 | $38–$1,524 | $163 |
| 2020 | $7,040 | — | — | $114 |
| 2021 | $1,900 | $900 | $25–$1,899 | $132 |
| 2022 | $0 | $136 | $28–$4,738 | $149 |
| 2023 | $105 | $139 | $48–$3,150 | $160 |
| 2024 | $2,126 | $1,077 | $71–$2,833 | $164 |
| 2025 | $27,228 | $225 | $91–$3,596 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 4 billing codesPaid by Medicare
$41,938
Medicare patients
858
Services billed
1,082
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 47% | |
| Cancer | 39% | |
| Ischemic heart disease | 37% | |
| Diabetes | 29% | |
| Chronic kidney disease | 28% | |
| Atrial fibrillation | 21% | |
| COPD | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Molecular Genetic Pathology in New York
Doctor Goldstein
Molecular Genetic Pathology · Bronx, NY
James Solomon
Molecular Genetic Pathology · New York, NY
Robert Burk
Molecular Genetic Pathology · Bronx, NY
Sanjay Mukhopadhyay
Molecular Genetic Pathology · Syracuse, NY
Tatyana Gindin
Molecular Genetic Pathology · New York, NY
Chad Vanderbilt
Molecular Genetic Pathology · New York, NY
Related records
Molecular Genetic Pathology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Molecular Genetic Pathology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.